Maze Therapeutics, Inc. (MAZE)
(Delayed Data from NSDQ)
$14.25 USD
-0.26 (-1.79%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $13.92 -0.33 (-2.32%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MAZE 14.25 -0.26(-1.79%)
Will MAZE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MAZE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for MAZE
12 Health Care Stocks Moving In Monday's After-Market Session
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Maze Therapeutics (MAZE) Receives Buy Rating from HC Wainwright & Co. | MAZE Stock News
Maze Therapeutics (MAZE) Receives Positive Rating and Outlook | MAZE Stock News
Maze Therapeutics initiated with bullish view at H.C. Wainwright, here's why